503b bulks list exclusion
How FDA Exclusion Costly Cuts Semaglutide Prices 30%
The FDA’s recent exclusion of semaglutide from the 503B bulks list is expected to lower compounding costs by roughly 30 percent, making the drug more affordable for patients and pharmacies. This change stems from regulatory clarification and could reshape pricing across the GLP-1 market. Medical Disclaimer: This article is